Business UpdateJun 15, 2026, 07:26 AM
Dyadic C1 Platform Gains Traction for Ebola Preparedness & Commercial Use
AI Summary
Dyadic International is experiencing increased interest in its proprietary C1 protein production platform, driven by global infectious disease preparedness efforts related to the Bundibugyo Ebola virus outbreak. The company highlights the platform's speed, scalability, and cost-effectiveness for rapidly manufacturing vaccines and monoclonal antibodies. Dyadic is also advancing commercial adoption across multiple high-growth markets, including biopharmaceuticals, life sciences, food, nutrition, and industrial applications, through various collaborations and product launches.
Key Highlights
- Dyadic's C1 platform can progress from codon-optimized viral gene sequence to purified antigen/antibody in approximately 15 days.
- The company is collaborating with Scripps Research to accelerate vaccine antigen and monoclonal antibody development for infectious diseases.
- Dyadic submitted research proposals to CEPI's Ebola funding call, incorporating the C1 platform for vaccine development.
- An initiative with Fondazione Biotecnopolo di Siena and the European Vaccines Hub focuses on Ebola and hantavirus antibody programs.
- Dyadic launched recombinant human albumin through Proliant Health & Biologicals and recombinant DNase I through Fermbox Bio.
- The DYAI-100 clinical study demonstrated C1-produced antigens were generally safe and well tolerated.
- Dyadic's C1 and Dapibus™ platforms target an estimated $25 billion market opportunity across various sectors.
Price Impact
More from DYAI